The increasing importance of digital in healthcare is upsetting the traditional drug and medical device development cycles. Digital companies are developing their technology faster, and bringing to market products that all too often have not been demonstrated to be of clinical value.

The failure to evaluate and analyze the potential of the proket induces a significant risk:

• It extends the market access process
.
• He can lead projects to new R&D phases
• It canendanger its company when R&D funding is no longer assured

This action is attached to the experimentation axis of the strategy.

The aim is to support projects aimed at evaluating the benefit of digital or AI-based medical devices. The results of rigorous evaluation projects should:

• Be able to justify the practical use
of the device tested.
• Determine access to common law, guaranteeing a recurring business model for companies demonstrating a significant medical service rendered.
• Be the cement of confidence in these new technologies among users and citizens alike
.

Calls for projects will be launched in successive waves every year. A support mechanism through the health clusters will be implemented.